Stryker Corp

Stryker Corp(SYK)股票分析

$317.400

-6.285 (-1.98%)收盘时

Loading chart…
High
331.500
Open
329.830
VWAP
321.92
Vol
2.14M
Mkt Cap
129.73B
Low
316.850
Amount
688.38M
EV/EBITDA, TTM
14.65

Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease.

AI analysis of Stryker Corp (SYK)

hold

Stryker Corp is currently a hold. The stock is priced at $330.69, with a forward P/E ratio of 21.88, which suggests it may be fairly valued for long-term growth. However, the RSI is at 49.47, indicating a neutral momentum, and hedge funds have increased selling by 119.77%, which raises concerns about market sentiment. The main risk is the ongoing supply chain disruptions impacting growth, as highlighted in recent earnings reports.

Analyst Ratings (27)

+35.58% upside
Buy
17 Buy
8 Hold
2 Sell
Current: 317.40
最低
390.00
平均
430.32
最高
465.00

Citi

2026-08-13

目标价

$399

Buy

Wolfe Research

2026-08-13

目标价

Peer Perform

Citizens

2026-08-03

目标价

$400

Outperform

RBC Capital

2026-07-31

目标价

$420

Outperform

BTIG

2026-07-31

目标价

$358

Buy

估值指标

The current forward P/E ratio for Stryker Corp (SYK) is 21.41, compared to its 5-year average forward P/E of 25.86.

Forward P/E

Undervalued
5Y Average P/E
25.86
Current P/E
21.41
高估
28.41
低估
23.31

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
21.21
Current EV/EBITDA
14.65
高估
23.16
低估
19.26

Forward P/S

Undervalued
5Y Average P/S
5.20
Current P/S
4.19
高估
5.81
低估
4.59

Alphio AI Price Scenarios for SYK

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SYK

$404.29

情景价格

B

Base

Base · 50%SYK

$362.50

情景价格

B

Bear

Bear · 25%SYK

$296.60

情景价格

Whales holding SYK

B

Bellevue Asset Management AG

+ HoldingSYK

+9.89%

3M Return

O

OrbiMed Advisors LLC

+ HoldingSYK

+6.93%

3M Return

F

Flossbach von Storch SE

+ HoldingSYK

+5.47%

3M Return

S

Scharf Investments, LLC

+ HoldingSYK

+4.58%

3M Return

V

Veritas Investment Management LLP

+ HoldingSYK

+4.53%

3M Return

V

Veritas Asset Management LLP

+ HoldingSYK

+4.46%

3M Return

事件时间线

2026-09-01 (ET)

10:00:00

Stryker Successfully Completes First Surgery Using Apple Vision Pro

2026-08-31 (ET)

16:30:00

Stryker Signs Agreement to Acquire ZuriMED

2026-08-26 (ET)

10:30:00

Canada Raises Tariffs on U.S. Steel and Aluminum to 50%

2026-08-18 (ET)

17:30:00

Stryker Awarded Significant Contract

资讯

SYK FAQ — answered by Alphio AI

Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Stryker Corp is currently a hold. The stock is priced at $330.69, with a forward P/E ratio of 21.88, which suggests it may be fairly valued for long-term growth. However, the RSI is at 49.47, indicating a neutral momentum, and hedge funds have increased selling by 119.77%, which raises concerns about market sentiment. The main risk is the ongoing supply chain disruptions impacting growth, as highlighted in recent earnings reports.

27 analysts cover SYK: 17 rate it Buy, 8 Hold and 2 Sell. The average price target is 430.32.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始